Fusen Pharmaceutical Company Limited (HKG:1652)

Market Cap	247.67M
Revenue (ttm)	346.95M
Net Income (ttm)	-200.90M
Shares Out	739.30M
EPS (ttm)	-0.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	111,000
Average Volume	108,200
Open	0.3350
Previous Close	0.3500
Day's Range	0.3150 - 0.3400
52-Week Range	0.2350 - 1.0500
Beta	0.26
RSI	41.08
Earnings Date	Aug 29, 2025

About HKG:1652

Fusen Pharmaceutical Company Limited, an investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. The company’s product portfolio includes Shuanghuanglian oral solutions and Shuanghuanglian injections; Sanhuang tablet; heat-clearing and detoxicating oral solutions; nicardipine hydrochloride injections; and other products. It also offers small and large volume injections, oral liquids, tablets, capsules, granules, traditional Chinese medicine extracts, and chemical sy...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 1,131
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1652

Financial Performance

In 2024, HKG:1652's revenue was 326.03 million, a decrease of -42.36% compared to the previous year's 565.61 million. Losses were -188.78 million, 420.4% more than in 2023.

Financial numbers in CNY